Prolactin inhibitors in oncology
Di Bella Method and Prolactin (PRL) inhibitors (e.g. Bromocriptine, Cabergoline and so on) in oncology
Cabergoline and/or Bromocriptine negatively regulate Prolactin, the ubiquitary mitogenic hormone. This effect is reinforced by Somatostatin and/or its analogues (cfr. Somatostatin in oncology, the overlooked evidences) by negatively regulating highly mitogenic molecules such as GH and GH-dependent growth factors. By activating their respective membrane receptors (GHR, GFR and PRLR), the GH, GF and PRL molecules trigger chemical reactions of phosphorylation, transferring the signal from the cellular membrane to the nucleus. The larger the amount of GHR in a tumour cell, the greater its capacity to use the GH, and thus to grow, both locally and also to expand remotely.
The dose-dependent relationship between receptor expression of GH in tumour cells and their speed and ability to expand locally and to migrate and produce metastases has been extensively demonstrated. Since it has been definitively and scientifically proved that a tumour is a growth, and that this growth depends on GH, GF and PRL, the obvious main therapeutic objective for the cure of any tumour cannot logically exclude the inhibition of GH, GF and PRL by means of Somatostatin and the prolactin inhibitors Cabergoline and/or Bromocriptine. The inhibition of tumour growth by blocking the growth hormone through its biological antidote, Somatostatin (SST), thus follows a simple, linear, understandable and mathematical logic (figure below).
In this figure growth hormone GH is in direct contact with the respective receptor GHR, at the level of the cellular membrane (in blue). The contact triggers transduction and amplification of the signal to the nucleus (in red). The reactions are protein-tyrosine kinase phosphorylation events. These reactions are blocked by somatostatin (SST) which, by activating its receptor SSTR, triggers OPPOSING enzymatic phosphatase systems which disactivate the protein-tyrosine kinase phosphorylation chain, inhibiting the neoplastic proliferation. This direct antitumoural action of SST on the tumour cell is combined with its equally potent indirect action, consisting of the reduction of the blood concentrations of GH and consequently of GF.
The same concept and the same therapeutic rationale apply to the pharmacological blocking of Prolactin by means of the relative inhibitors, such as Bromocriptine and Cabergoline. The same concept and the same therapeutic rationale apply in oncology to the blocking of estrogens and androgens in the respective hormone-dependent tumours. But oncology still does not understand the need to extend the same concept to the inhibition of the most potent ubiquitary oncogenes: GH (growth hormone), (GH-dependent) GFs (growth factors) and PRL.
The Di Bella Method (A Fixed Part) uses agonists Cabergoline and/or Bromocriptine.
Inhibitors of Prolactin have the following documented mitogenic activities with a great number of works published: In Vitro, In Vivo (Animal Only), Review, Editorial, Meta-analysis and In Vivo (Human Only).
Only In Vitro Research (Isolated organs, tissues, cells, or biochemical systems - IUPAC Gold Book definition)
-
- 1974 Jul: Growth-hormone dependence among human breast cancers;
- 1979 Nov: Prolactin receptors in human breast cancer cells in long-term tissue culture;
- 1982 Nov: Prolactin receptors in human breast cancer;
- 1983 Apr: Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture;
- 1985 Sep: Prolactin-inducible proteins in human breast cancer cells;
- 1987 Jul: Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in long-term tissue culture;
- 1988 Feb: Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin;
- 1990 Jan: Purification and partial sequence of the rabbit mammary gland prolactin receptor;
- 1990 Aug: Regulation of interleukin 2-driven T-lymphocyte proliferation by prolactin;
- 1994 Dec: Evidence for a second receptor binding site on human prolactin;
- 1995 Mar: Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop;
- 1995 Jun: Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines;
- 1995 Jun: Prolactin synthesis and secretion by human breast cancer cells;
- 1996 Jan: In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate;
- 1997 Feb: Prolactin and prolactin receptors are expressed and functioning in human prostate;
- 1997 May: Prolactin stimulates the JAK2 and focal adhesion kinase pathways in human breast carcinoma T47-D cells;
- 1997 Dec: Expression of prolactin and its receptor in human breast carcinoma;
- 1998 Oct: Role of Mammary Prolactin in Carcinogenesis;
- 1999 Nov: A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis;
- 1999 Nov: Prolactin as a chemoattractant for human breast carcinoma;
- 2000 Oct: Advantages of heterologous expression of human D2long dopamine receptors in human neuroblastoma SH-SY5Y over human embryonic kidney 293 cells;
- 2001 Jan: Ectopic production of prolactin by colorectal adenocarcinoma;
- 2001 Apr: Dopamine D2 receptor gene expression in human adenohypophysial adenomas;
- 2001 Aug: A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice;
- 2002 Jun: Expression of functional prolactin and its receptor in human colorectal cancer;
- 2002 Jul: Prolactin influences proliferation and apoptosis of a human IgE secreting myeloma cell line, U266;
- 2003 Feb: Conserved motifs in somatostatin, D2-dopamine, and alpha 2B-adrenergic receptors for inhibiting the Na-H exchanger, NHE1;
- 2003 Sep: Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL;
- 2004 Jul: Prolactin acts as a potent survival factor for human breast cancer cell lines;
- 2004 Aug: Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma;
- 2007 Apr: Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway;
- 2007 Oct: Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells;
- 2008 May: Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas;
- 2008 Jun: Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study;
- 2008 Aug: Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity;
- 2008 Oct: Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro;
- 2008 Dec: Prolactin blocks nuclear translocation of VDR by regulating its interaction with BRCA1 in osteosarcoma cells;
- 2009 Jan: Activation of the unliganded estrogen receptor by prolactin in breast cancer cells;
- 2009 Jan: Analyses of factors influencing the acute effect of octreotide in growth hormone-secreting adenomas;
- 2009 Jan: Re-evaluation of the prolactin receptor expression in human breast cancer;
- 2009 Mar: Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly;
- 2009 Mar: Impaired turnover of prolactin receptor contributes to transformation of human breast cells;
- 2009 May: Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase;
- 2009 Jun: Biological significance of prolactin in gynecologic cancers;
- 2009 Jul: The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways;
- 2009 Dec: A mimic of phosphorylated prolactin inhibits human breast cancer cell proliferation via upregulation of p21 waf1;
- 2010 Feb: The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells;
- 2011 Apr: Prolactin receptor is a negative prognostic factor in patients with squamous cell carcinoma of the head and neck;
- 2011 Jun: Prolactin increases survival and migration of ovarian cancer cells: importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists;
- 2012 Jan: Increased expression of the prolactin receptor is associated with malignant laryngeal tumors;
- 2014 Feb: Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma;
- 2015 Jun: Anti-metastatic outcome of isoform-specific prolactin receptor targeting in breast cancer;
- 2015 Nov: The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation;
- 2015 Dec: Prolactin Promotes Breast Cancer Cell Migration through Actin Cytoskeleton Remodeling;
- 2016 Mar: Prolactin inhibits a major tumor-suppressive function of wild type BRCA1;
- 2017 Apr: Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells;
- 2017 Sep: Sex-related hormone receptor in laryngeal squamous cell carcinoma: correlation with androgen estrogen-ɑ and prolactin receptor expression and influence of prognosis;
- 2018 Oct: Repurposing of Bromocriptine for Cancer Therapy;
- 2019 Jan: Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma;
- 2019 Apr: Concomitant Expression of Prolactin Receptor and TGFβ Receptors in Breast Cancer: Association with Less Aggressive Phenotype and Favorable Patient Outcome;
- 2019 May: An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation;
- 2019 Jun: Dopamine D1 receptor agonists inhibit lung metastasis of breast cancer reducing cancer stemness;
- 2019 Sep: A Novel Multi-Target Small Molecule, LCC-09, Inhibits Stemness and Therapy-Resistant Phenotypes of Glioblastoma Cells by Increasing miR-34a and Deregulating the DRD4/Akt/mTOR Signaling Axis;
- 2020 Mar: Therapeutic Effect of a Novel Chimeric Molecule Targeting Both Somatostatin and Dopamine Receptors on Growth Hormone-Secreting Pituitary Adenomas;
- 1979 Nov: Inhibition of mammary tumorigenesis in carcinogen-treated Lewis rats by suppression of prolactin secretion;
- 1980 Sep: Synergistic effect of chronic prolactin suppression and retinoid treatment in the prophylaxis of N-methyl-N-nitrosourea-induced mammary tumorigenesis in female Sprague-Dawley rats;
- 1982 Jan: Influence of prolactin and growth hormone on rat mammary tumors induced by N-nitrosomethylurea;
- 1988 Feb: Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin;
- 1990 Jan: Purification and partial sequence of the rabbit mammary gland prolactin receptor;
- 1998 Oct: Role of Mammary Prolactin in Carcinogenesis;
- 2001 Jan: Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects;
- 2001 Aug: A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice;
- 2001 Oct: Anti-tumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: anti-proliferative and pro-apoptotic effects;
- 2007 Apr: Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway;
- 2007 Oct: Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells;
- 2008 Dec: Long-term treatment with bromocriptine inhibits endometrial adenocarcinoma development in rats;
- 2009 Jun: Biological significance of prolactin in gynecologic cancers;
- 2010 Feb: The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells;
- 2014 Feb: Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma;
- 2015 Jun: Anti-metastatic outcome of isoform-specific prolactin receptor targeting in breast cancer;
- 2019 Jan: Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma;
- 2019 Jun: Dopamine D1 receptor agonists inhibit lung metastasis of breast cancer reducing cancer stemness;
- 2019 Sep: A Novel Multi-Target Small Molecule, LCC-09, Inhibits Stemness and Therapy-Resistant Phenotypes of Glioblastoma Cells by Increasing miR-34a and Deregulating the DRD4/Akt/mTOR Signaling Axis;
- 2020 Mar: Therapeutic Effect of a Novel Chimeric Molecule Targeting Both Somatostatin and Dopamine Receptors on Growth Hormone-Secreting Pituitary Adenomas;
- 1991 Aug: The prolactin/growth hormone receptor family;
- 1994 Mar: Effect of prolactin on the prostate;
- 1995 May: Effects of growth hormone and prolactin immune development and function;
- 1996 Sep: Prolactin and growth hormone receptors (Goffin & Kelly);
- 1996 Dec: Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects;
- 1998 Oct: A role for growth hormone and prolactin in leukaemia and lymphoma?;
- 2002 Aug: Prolactin as an autocrine/paracrine growth factor in human cancer;
- 2003 Feb: The role of prolactin in mammary carcinoma;
- 2004 Feb: The structural basis for biological signaling, regulation, and specificity in the growth hormone-prolactin system of hormones and receptors;
- 2005 Apr: Development and potential clinical uses of human prolactin receptor antagonists;
- 2006 Mar: Prolactin and breast cancer risk;
- 2007 Apr: Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours;
- 2007 Dec: Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas;
- 2008 Jan: Rational design of competitive prolactin/growth hormone receptor antagonists;
- 2008 Jul: Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome;
- 2008 Jul: Somatostatin-dopamine ligands in the treatment of pituitary adenomas;
- 2009 Sep: The role of prolactin in human breast cancer;
- 2009 Dec: Nutrition and orthomolecular supplementation in lung cancer patients;
- 2010 Sep: Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor;
- 2011 Feb: Place of cabergoline in acromegaly: a meta-analysis;
- 2011 Oct: Prolactin regulation of the prostate gland: a female player in a male game;
- 2011 Nov: Hypothesis: prolactin is tumorigenic to human breast: dispelling the myth that prolactin-induced mammary tumors are rodent-specific;
- 2012 Jan-Mar: Sex hormones in head and neck cancer: Current knowledge and perspectives;
- 2012 Dec: Prolactin and cancer: Has the orphan finally found a home?;
- 2014 Apr: Minireview: Extrapituitary prolactin: an update on the distribution, regulation, and functions;
- 2014 Nov: Sex hormones in gender-specific risk for head and neck cancer: A review;
- 2015 Sep: The prolactin receptor: Diverse and emerging roles in pathophysiology;
- 2016 Sep: Prolactin receptor in breast cancer: marker for metastatic risk;
- 2018 Sep: The over-expression of GH/GHR in tumour tissues with respect to healthy ones confirms its oncogenic role and the consequent oncosuppressor role of its physiological inhibitor, somatostatin: a review of the literature (Di Bella's Foundation);
- 2019 Feb: A Proposed Efficacious Treatment with Clioquinol (Zinc Ionophore) and Cabergoline (Prolactin Dopamine Agonist) for the Treatment of Terminal Androgen-independent Prostate Cancer. Why and How?;
- 2019 Jun: The Suppression of Prolactin is required for the Treatment of Advanced Prostate Cancer;
- 2020 Sep: The role of the prolactin receptor pathway in the pathogenesis of glioblastoma: what do we know so far?.
Commentary - Editorial - Letter to the Editor - Correspondence
- 2014 Mar: Dopamine signaling: target in glioblastoma;
Meta-Analysis, Pooled Analysis and Narrative Reviews
In Vivo (Human Only: Case Reports/Series, Clinical Trials, Comparative Studies, Randomized Controlled Trials and Retrospective Studies)
- 1976 Mar: Plasma prolactin responses to thyrotropin-releasing hormone in patients with breast cancer;
- 1981 Jan: Serum prolactin after chest wall surgery: elevated levels after mastectomy;
- 1984 Sep: Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer;
- 1984 Dec: High serum prolactin associated with poor prognosis in carcinoma of the prostate;
- 1985 Aug: Elevated growth hormone levels in sera from breast cancer patients;
- 1986 Jul: A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs;
- 1986 Jul: Prolactin secreting renal cell carcinoma;
- 1988 Mar: Perioperative bromocriptine adjuvant treatment for operable breast cancer;
- 1990 May: Plasma prolactin as an indicator of disease progression in advanced breast cancer;
- 1991 Oct: Combination of a GnRH agonist with an antiandrogen or bromocriptine in the treatment of prostatic cancer; slight potentiation of antigonadal effects;
- 1993 Feb: Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide;
- 1994 Feb: Plasma prolactin in patients with colorectal cancer. Value in follow-up and as a prognosticator;
- 1995 Jun: A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate;
- 1995 Sep: Plasma and tumor prolactin in colorectal cancer patients;
- 1998 Jan: Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up;
- 1998 Jul-Aug: A phase II study of bromocriptine in patients with androgen-independent prostate cancer;
- 2000 Feb: Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia;
- 2000 May: Prolactin as a local growth promoter in patients with locally advanced tongue cancer: GCRI experience;
- 2000 Sep: Prolactin as a local growth promoter in patients with breast cancer: GCRI experience;
- 2001 Jan: Ectopic production of prolactin by colorectal adenocarcinoma;
- 2001 Apr: Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin's lymphomas at advanced stage: results of a phase II trial;
- 2004 Nov-Dec: Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer;
- 2004 Dec: Plasma prolactin in patients with colorectal cancer;
- 2006 Feb: Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status;
- 2006 Oct: Dopamine receptor expression and function in corticotroph ectopic tumors;
- 2006 Nov-Dec: Relapse of high-grade non-Hodgkin's lymphoma after autologous stem cell transplantation: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, melatonin, retinoids, and ACTH;
- 2007 Jan-Feb: Low-grade non-Hodgkin lymphoma at advanced stage: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, retinoids, and melatonin;
- 2007 Feb: Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status;
- 2007 Mar: A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer;
- 2008 May: Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas;
- 2008 Jul: Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly;
- 2008 Dec: Complete objective response to biological therapy of plurifocal breast carcinoma (Di Bella's Method, Di Bella's Foundation);
- 2009 Jan: An attempt at conservative treatment in selected cases of type I endometrial carcinoma (stage I a/G1) in young women;
- 2009 Jan: Analyses of factors influencing the acute effect of octreotide in growth hormone-secreting adenomas;
- 2009 Jun: Chronic lymphocytic leukemia: long-lasting remission with combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH;
- 2009 Aug: Complete objective response of oesophageal squamocellular carcinoma to biological treatment (Di Bella's Method, Di Bella's Foundation);
- 2009 Oct: Complete objective response of neuroblastoma to biological treatment (Di Bella's Method, Di Bella's Foundation);
- 2011 Apr: Prolactin receptor is a negative prognostic factor in patients with squamous cell carcinoma of the head and neck;
- 2012 Jan: The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck (Di Bella's Method, Di Bella's Foundation);
- 2012 Feb: The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer (Di Bella's Method, Di Bella's Foundation);
- 2012 Dec: The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 55 cases of lymphomas (Di Bella's Method, Di Bella's Foundation);
- 2013 Jan: The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature (Di Bella's Method, Di Bella's Foundation);
- 2013 Dec: Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary repor; (Di Bella's Method, Di Bella's Foundation);
- 2014 Jan: Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas;
- 2015 May: Recurrent Glioblastoma Multiforme (grade IV - WHO 2007): A case of complete objective response - Concomitant administration of Somatostatin / Octreotide, Retinoids, Vit E, Vit D3, Vit C, Melatonin, D2 R agonists (Di Bella Method - DBM) associated with Temolozomide (Di Bella's Method, Di Bella's Foundation);
- 2016 Feb: Congenital fibrosarcoma in complete remission with Somatostatin, Bromocriptine, Retinoids, Vitamin D3, Vitamin E, Vitamin C, Melatonin, Calcium, Chondroitin sulfate associated with low doses of Cyclophosphamide in a 14-year Follow up (Di Bella's Method, Di Bella's Foundation);
- 2017 Jul: A pilot study of cabergoline for the treatment of metastatic breast cancer;
- 2017 Sep: Sex-related hormone receptor in laryngeal squamous cell carcinoma: correlation with androgen estrogen-ɑ and prolactin receptor expression and influence of prognosis;
- 2017 Dec: Complete objective response, stable for 5 years, with the Di Bella Method, of multiple-metastatic carcinoma of the breast (Di Bella's Method, Di Bella's Foundation);
- 2018 May: The Synergism of Somatostatin, Melatonin, Vitamins Prolactin and Estrogen Inhibitors Increased Survival, Objective Response and Performance Status In 297 Cases of Breast Cancer (Di Bella's Method, Di Bella's Foundation);
- 2019 Mar: A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial;
- 2019 May: A Novel Patient Case Report to Show the Successful Termination of Untreatable Androgen-independent Prostate Cancer: Treatment with Cabergoline (Dopamine agonist);
- 2020 Apr: Upregulation of Prolactin Receptor Expression and Activation of Prolactin Signaling in an Aggressive Triple-Negative Breast Carcinoma During Pregnancy: A Case Report;
- 2021 Nov: A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness (Di Bella's Method, Di Bella's Foundation);
- 2022 Jun: A Retrospective Observational Study on Cases of Sarcoma Treated with the Di Bella Method: Rationale and Effectiveness (Di Bella's Method, Di Bella's Foundation);
- 2022 Sep: A retrospective observational study on cases of osteosarcomas treated with a multitherapy: The rationale and effectiveness (Di Bella's Method, Di Bella's Foundation);